Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Selecky

Sports Medicine Chula Vista, CA Medical Doctor

NPI 1669414850 CMS profile 1308720

955 Lane Ave, Suite 200, Chula Vista, CA 91914

Open in the dashboard

General payments

$3,898

55 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Selecky of Chula Vista, CA is reported in the CMS Open Payments database as having received $3,898 across 55 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 38th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $727 10
2024 General $654 8
2023 General $666 7
2022 General $476 7
2021 General $369 5
2020 General $100 3
2019 General $906 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Selecky
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Mark Selecky were reported at $727. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Mark Selecky Sports Medicine median Middle half National median
2019 $906 $1,176 $199–$4,249 $163
2020 $100 $708 $96–$2,890 $114
2021 $369 $1,213 $152–$3,994 $132
2022 $476 $1,230 $159–$3,998 $149
2023 $666 $584 $146–$2,836 $160
2024 $654 $628 $163–$3,168 $164
2025 $727 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,427 17 payments
  2. Zimmer Biomet Holdings, Inc. $368 6 payments
  3. Elevate Surgical CO $273 2 payments
  4. DePuy Synthes Sales Inc. $223 6 payments
  5. Stryker Corporation $209 3 payments
  6. Acumed LLC $162 2 payments
  7. Myoscience Inc. $156 1 payment
  8. Miach Orthopaedics, Inc. $137 1 payment
  9. Breg, Inc $128 1 payment
  10. Amgen Inc. $122 1 payment
  11. Other $693 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,876 54 payments
  2. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. Regeneten Sports Med Shoulder $278 2 payments
  2. Katalyst Bipolar Radial Head System $242 2 payments
  3. TRIATHLON $209 3 payments
  4. SERFAS ENERGY $161 2 payments
  5. 1588 $161 2 payments
  6. iovera System $156 1 payment
  7. REGENETEN Extremities & Limb Restoration $154 1 payment
  8. Avance $151 2 payments
  9. Samples Biologics $149 1 payment
  10. Bone Anchors with Arthroscopic Delivery System $149 1 payment
  11. Other $2,829 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

78

Median for Sports Medicine: 144

Drug cost

$451

Median for Sports Medicine: $1,027

Branded share of claims

23.1%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Naproxen Generic 23 $182
Ondansetron Hcl Generic 17 $102
Omeprazole Generic 20 $86
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 18 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$35,354

Of which drugs: $256

Medicare patients

80

Average age 74

Services billed

355

51 women, 29 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 61%
Diabetes 33%
Ischemic heart disease 18%
Depression 15%
Heart failure 14%
Atrial fibrillation 14%
Chronic kidney disease 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 16 47 $256

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record